You are here: Industry Insights > FORMA Therapeutics

News List

FORMA Therapeutics receives FDA orphan drug designation for FT-4202 to treat sickle cell disease pharmaceutical-business-review
April 20, 2020
FORMA Therapeutics, a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers.
Ubiquigent, Forma Therapeutics collaborate for DUB inhibitors biospectrumasia
April 08, 2018
The collaboration builds on an existing long term relationship between the parties whereby FORMA has accessed Ubiquigent’s DUBprofiler™ platform for the screening of test compounds
Ubiquigent, Forma Therapeutics collaborate for DUB inhibitors biospectrumasia
April 08, 2018
The collaboration builds on an existing long term relationship between the parties whereby FORMA has accessed Ubiquigent’s DUBprofiler™ platform for the screening of test compounds
FORMA Therapeutics Collaborates with Arpeggio Biosciences to Explore Translational Utility of Drug Candidates biospace
March 27, 2018
FORMA Therapeutics and Arpeggio Biosciences today announced a collaboration to utilize Arpeggio Biosciences’ proprietary technology to supplement FORMA’s analysis of the biological effects of its potential drug candidates.